Ketamine ameliorates postpartum depression-like behaviors in rats exposed to sevoflurane during pregnancy through the AMPK/SIRT1/NLRP3 pathway.
H. Xue, Xu Yang, Shihui Kuai, Yinong Zhang, Yufei Jia, Zi-yi Wu, Ping Zhao
Journal of Affective Disorders February 14, 2026 DOI: 10.1016/j.jad.2026.121439 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractRepeated exposure to the general anesthetic sevoflurane during mid-gestation induces depression-like behaviors in postpartum rats. Pregnant rats exposed to 3% sevoflurane for two hours on gestational days 13-15 showed increased immobility in the forced swim test, prolonged feeding latency, reduced food consumption, and decreased movement in the open field test on postpartum day 1. These behaviors were accompanied by decreased AMPK/SIRT1 expression, activation of the NLRP3 inflammasome, microglial activation, and increased inflammatory cytokines in the hippocampus. Treatment with AICAR (an AMPK agonist), MCC950 (an NLRP3 antagonist), minocycline (a microglial activation inhibitor), or ketamine alleviated these effects, while dorsomorphin (an AMPK antagonist) reversed ketamine's antidepressant effects. The findings indicate that ketamine alleviates postpartum depression-like behaviors by reducing microglial neuroinflammation and NLRP3 inflammasome activation via the AMPK/SIRT1 signaling pathway.
Study at a glance
| Characteristics | Animal experiment Peer reviewed |
|---|---|
| Population | Pregnant rats |
| Interventions | Sevoflurane AICAR MCC950 minocycline ketamine dorsomorphin |
| Dose | 3% sevoflurane for 2 h |
| Duration | Gestational days 13-15 exposure; assessed on postpartum days 1, 7, 14, and 21 |
| Keywords | Medicine |
| Key finding | Repeated sevoflurane exposure during mid-gestation induces depression-like behaviors in postpartum rats, and ketamine alleviates these behaviors by reducing microglial neuroinflammation and NLRP3 inflammasome activation via the AMPK/SIRT1 signaling pathway. |
Abstract
General anesthetics can exert significant adverse effects on the central nervous system. This study aimed to investigate whether repeated exposure to sevoflurane induces depression-like behaviors in postpartum rats. Pregnant rats were exposed to 3% sevoflurane for 2 h on gestational days 13-15. Emotional behaviors were assessed on postpartum days 1, 7, 14, and 21. Hippocampal protein levels associated with the AMPK/SIRT1/NLRP3 signaling pathway were analyzed by Western blotting. Microglial activation and inflammasome expression were analyzed by immunofluorescence, and cytokine levels (IL-1β, IL-18, TNF-α) by ELISA. To explore the role of the AMPK/SIRT1/NLRP3 pathway and neuroinflammation in postpartum maternal depression, rats were treated with AICAR (an AMPK agonist), MCC950 (an NLRP3 antagonist), and minocycline (a microglial activation inhibitor). Additionally, ketamine, with or without dorsomorphin (an AMPK antagonist), was administered to assess whether ketamine's antidepressant effects are mediated through this pathway. Sevoflurane-exposed rats exhibited behavioral impairments on postpartum day 1, including increased immobility in the forced swim test, prolonged feeding latency, reduced food consumption in the novelty-suppressed feeding test, and decreased movement in the open field test. These behaviors were accompanied by decreased AMPK/SIRT1 expression, NLRP3 inflammasome activation, and microglial activation in the hippocampus, resulting in significant inflammatory cytokine release. Treatment with AICAR, MCC950, minocycline, or ketamine alleviated these effects, while dorsomorphin reversed the antidepressant effects of ketamine. Our findings indicate that repeated sevoflurane exposure during mid-gestation induces depression-like behaviors in postpartum rats, and that ketamine alleviates these behaviors by reducing microglial neuroinflammation and NLRP3 inflammasome activation via the AMPK/SIRT1 signaling pathway.